We recently published 10 Stocks Jim Cramer Talked About. Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer talked ...

Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...

Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted ...

Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched ...

Pfizer is penning a cancer discovery pact with Cartography Biosciences that could max out at $865 million biobucks. | Pfizer ...

Madrigal Pharma is reheating a drug for metabolic dysfunction-associated steatohepatitis (MASH) put on ice by Pfizer, hoping ...

Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an ...

Pfizer isn’t stopping to smell the roses on its speed run to secure a full FDA approval for its Braftovi combination therapy. After securing a unique accelerated approval not quite six months ago, the ...

Vertex and Medtronic could see strong momentum this year, while Pfizer is still facing challenges. Regardless of what happens ...

Pfizer's oncology portfolio has produced a second positive phase 3 trial in HER2-positive breast cancer in the span of about a year. This time, the drug that delivered the positive readout is Tukysa, ...

The end of a short-lived, COVID-related revenue surge has brought Pfizer's stock lower. But sellers have ignored all the ...

Pfizer is racing towards patent cliffs that will lead to even worse financial results. Vertex Pharmaceuticals is posting strong revenue growth and excellent clinical progress. As a result, Vertex ...